Centessa Pharmaceuticals (CNTA) Income towards Parent Company: 2019-2024
Historic Income towards Parent Company for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$235.8 million.
- Centessa Pharmaceuticals' Income towards Parent Company fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
- As of FY2024, Centessa Pharmaceuticals' Income towards Parent Company stood at -$235.8 million, which was down 56.04% from -$151.1 million recorded in FY2023.
- Centessa Pharmaceuticals' 5-year Income towards Parent Company high stood at -$10.7 million for FY2020, and its period low was -$381.1 million during FY2021.
- In the last 3 years, Centessa Pharmaceuticals' Income towards Parent Company had a median value of -$216.2 million in 2022 and averaged -$201.0 million.
- As far as peak fluctuations go, Centessa Pharmaceuticals' Income towards Parent Company tumbled by 3,473.77% in 2021, and later soared by 43.26% in 2022.
- Centessa Pharmaceuticals' Income towards Parent Company (Yearly) stood at -$10.7 million in 2020, then tumbled by 3,473.77% to -$381.1 million in 2021, then skyrocketed by 43.26% to -$216.2 million in 2022, then spiked by 30.12% to -$151.1 million in 2023, then plummeted by 56.04% to -$235.8 million in 2024.